We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
Read MoreHide Full Article
Achillion Pharmaceuticals, Inc. incurred a loss of 12 cents per share in the fourth quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 17 cents.
The company did not generate any revenues in the reported quarter in absence of an approved product in its portfolio.
Shares of Achillion have soared 67.3% so far this year, outperforming the industry’s increase of 11.1%.
Quarter in Detail
Research and development (R&D) expenses decreased nearly 20.8% from the year-earlier period to $12.2 million, primarily due to decreased personnel costs and low research costs related to ACH-5228.
General and administrative expenses declined 33.7% year over year to $5.9 million, thanks to payment of the underwriting fees.
Pipeline Update
Two phase II studies are evaluating the first-generation oral factor D inhibitor, ACH-4471, on patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G).
Last December, Achillion announced positive interim data from the clinical study, evaluating its factor D inhibitor – ACH-4471. Results from the mid-stage analyses on ACH-4471 demonstrated a proof of concept as monotherapy or in combination with a C5 Inhibitor in PNH patients. Moreover, ACH-4471 achieved a proof of mechanism in C3G patients as well.
The company plans to report updated interim findings on ACH-4471 for PNH in combination with a C5 inhibitor during the second quarter of 2019. It plans to present data from PNH and C3G programs on ACH-4471 to the FDA in fourth-quarter 2019.
Achillion is also developing its next-generation factor D inhibitors, ACH-5228 and ACH-5548, in two separate phase I studies.
Last December, Achillion announced favorable interim data from the clinical studies, investigating its factor D inhibitors — ACH-5228 and ACH-5548. Outcomes from the early-stage probes examining ACH-5228 and ACH-5548 showed to have potential of higher alternative pathway inhibition along with a reduced dosing frequency.
Meanwhile, the company recently initiated a phase I ex-U.S. multiple ascending dose (MAD) study of ACH-5228 in the EU. On successful completion, Achillion plans to submit an investigational new drug (IND) application in the fourth quarter of 2019 to begin a phase I assessment in the United States.
Achillion expects net cash usage to be approximately $80 million in 2019.
Achillion Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Achillion currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Celgene Corporation , Kamada Ltd. and Compugen Ltd. (CGEN - Free Report) , all sporting a Zacks Rank #1(Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Celgene’s earnings estimates have been revised 7.8% upward for 2019 over the past 60 days. The stock has surged 33.7% so far this year.
Kamada’s earnings estimates have moved 34.3% north for 2019 over the past 60 days. The stock has rallied 18.4% so far this year.
Compugen’s loss per share estimates have been narrowed 24% for 2019 in the last 60 days. The stock has soared 55.3% so far this year.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
Achillion Pharmaceuticals, Inc. incurred a loss of 12 cents per share in the fourth quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 17 cents.
The company did not generate any revenues in the reported quarter in absence of an approved product in its portfolio.
Shares of Achillion have soared 67.3% so far this year, outperforming the industry’s increase of 11.1%.
Quarter in Detail
Research and development (R&D) expenses decreased nearly 20.8% from the year-earlier period to $12.2 million, primarily due to decreased personnel costs and low research costs related to ACH-5228.
General and administrative expenses declined 33.7% year over year to $5.9 million, thanks to payment of the underwriting fees.
Pipeline Update
Two phase II studies are evaluating the first-generation oral factor D inhibitor, ACH-4471, on patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G).
Last December, Achillion announced positive interim data from the clinical study, evaluating its factor D inhibitor – ACH-4471. Results from the mid-stage analyses on ACH-4471 demonstrated a proof of concept as monotherapy or in combination with a C5 Inhibitor in PNH patients. Moreover, ACH-4471 achieved a proof of mechanism in C3G patients as well.
The company plans to report updated interim findings on ACH-4471 for PNH in combination with a C5 inhibitor during the second quarter of 2019. It plans to present data from PNH and C3G programs on ACH-4471 to the FDA in fourth-quarter 2019.
Achillion is also developing its next-generation factor D inhibitors, ACH-5228 and ACH-5548, in two separate phase I studies.
Last December, Achillion announced favorable interim data from the clinical studies, investigating its factor D inhibitors — ACH-5228 and ACH-5548. Outcomes from the early-stage probes examining ACH-5228 and ACH-5548 showed to have potential of higher alternative pathway inhibition along with a reduced dosing frequency.
Meanwhile, the company recently initiated a phase I ex-U.S. multiple ascending dose (MAD) study of ACH-5228 in the EU. On successful completion, Achillion plans to submit an investigational new drug (IND) application in the fourth quarter of 2019 to begin a phase I assessment in the United States.
Achillion expects net cash usage to be approximately $80 million in 2019.
Achillion Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Achillion Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Achillion Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Achillion currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Celgene Corporation , Kamada Ltd. and Compugen Ltd. (CGEN - Free Report) , all sporting a Zacks Rank #1(Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Celgene’s earnings estimates have been revised 7.8% upward for 2019 over the past 60 days. The stock has surged 33.7% so far this year.
Kamada’s earnings estimates have moved 34.3% north for 2019 over the past 60 days. The stock has rallied 18.4% so far this year.
Compugen’s loss per share estimates have been narrowed 24% for 2019 in the last 60 days. The stock has soared 55.3% so far this year.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>